Etoposide resistance in MCF-7 breast cancer cell line is marked by multiple mechanisms

Biomedicine and Pharmacotherapy

Volumn 68, Issue 3, 2014, Pages 351-355

  Alpsoy, Aktan ^a   Yasa, Seda ^a   Gündüz, Ufuk ^a  

^a MIDDLE EAST TECHNICAL UNIVERSITY   (Turkey)

Author keywords

Breast cancer; Chemoresistance; Etoposide

Indexed keywords

ETOPOSIDE; MULTIDRUG RESISTANCE ASSOCIATED PROTEIN 1; RNA; CARRIER PROTEIN; DNA BINDING PROTEIN; DNA TOPOISOMERASE (ATP HYDROLYSING); DNA TOPOISOMERASE II ALPHA; MULTIDRUG RESISTANCE PROTEIN; MULTIDRUG RESISTANCE-ASSOCIATED PROTEIN 1; NUCLEAR PROTEIN; TOPBP1 PROTEIN, HUMAN; TUMOR ANTIGEN; UBIQUITIN PROTEIN LIGASE; UBR5 PROTEIN, HUMAN;

ARTICLE; BREAST ADENOCARCINOMA; CANCER CELL CULTURE; CANCER RESISTANCE; CELL PROLIFERATION ASSAY; CONTROLLED STUDY; DNA DAMAGE; DRUG CYTOTOXICITY; ENZYME ACTIVITY; GENE EXPRESSION; HUMAN; HUMAN CELL; IC 50; IN VITRO STUDY; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA EXTRACTION; UPREGULATION; ANTAGONISTS AND INHIBITORS; CELL SURVIVAL; CULTURE TECHNIQUE; DRUG EFFECTS; DRUG RESISTANCE; GENETICS; MCF 7 CELL LINE; METABOLISM;

ANTIGENS, NEOPLASM; CARRIER PROTEINS; CELL CULTURE TECHNIQUES; CELL SURVIVAL; DNA DAMAGE; DNA TOPOISOMERASES, TYPE II; DNA-BINDING PROTEINS; DRUG RESISTANCE, NEOPLASM; ETOPOSIDE; GENE EXPRESSION; HUMANS; MCF-7 CELLS; MULTIDRUG RESISTANCE-ASSOCIATED PROTEINS; NUCLEAR PROTEINS; RNA; UBIQUITIN-PROTEIN LIGASES;

EID: 84899492114     PISSN: 07533322     EISSN: 19506007     Source Type: Journal    
DOI: 10.1016/j.biopha.2013.09.007     Document Type: Article

References (23)

1. Gillet J., Gottesman M.M. Mechanisms of multi drug resistance in cancer. Multidrug resistance in cancer 2010, 596. Humana Press. J. Zhou (Ed.).
2. Hande K.R. Etoposide: four decades of development of a topoisomerase II inhibitor. Eur J Cancer 1998, 34(10):1514-1521.
3. Burden D.A., Osheroff N. Mechanism of action of eukaryotic topoisomerase II and drugs targeted to the enzyme. Biochim Biophys Acta 1998, 1400(1-3):139-154.
4. Schneider E., Horton J.K., Yang C., Nakagawa M., Cowan K.H. Multidrug resistance-associated protein gene overexpression and reduced drug sensitivity of topoisomerase II in a human breast carcinoma MCF-7 cell line selected for etoposide resistance. Cancer Res 1994, 54:152-158.
5. Fedier A., Schwarz V.A., Walt H., Carpini R.D., Haller U., Fink D. Resistance to topoisomerase poisons due to loss of DNA mismatch repair. Int J Cancer 2001, 93(4):571-576.
6. Kaplan E., Gündüz U. Expression analysis of TOP2A, MSH2 and MLH1 genes in MCF-7 cells at different levels of etoposide resistance. Biomed Pharmacother 2012, 66(1):29-35.
7. Szak G., Kin K., To W., Polg O., Robey R.W., Bates S.E. Multidrug resistance mediated byMDR-ABC transporters. Drug Resistance in Cancer Cells 2009, 1-20. Springer. Z. Siddik, K. Mehta (Eds.).
8. Going J.J., Nixon C., Dornan E.S., Boner W., Donaldson M.M., Morgan I.M. Aberrant expression of TopBP1 in breast cancer. Histopathology 2007, 50(4):418-424.
9. Forma E., Krzeslak A., Bernaciak M., Romanowicz-Makowska H., Brys M. Expression of TopBP1 in hereditary breast cancer. Mol Biol Rep 2012, 39(7):7795-7804.
10. O'Brien P.M., Davies M.J., Scurry J.P., Smith A.N., Barton C.A., Henderson M.J., et al. The E3 ubiquitin ligase EDD is an adverse prognostic factor for serous epithelial ovarian cancer and modulates cisplatin resistance in vitro. Br J Cancer 2008, 98(6):1085-1093.
11. Liu K., Ling S., Lin W.C. TopBP1 mediates mutant p53 gain of function through NF-Y and p63/p73. Mol Cell Biol 2011, 31(22):4464-4481. 10.
12. Dönmez Y., Gündüz U. Reversal of multidrug resistance by small interfering RNA (siRNA) in doxorubicin-resistant MCF-7 breast cancer cells. Biomed Pharmacother 2011, 65(2):85-89.
13. -δδCt method. Methods 2001, 25:402-408.
14. Bradford M.M. Rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 1976, 72:248-254.
15. Takano H., Kohno K., Ono M., Takano H., Kohno K., Ono M., et al. Increased phosphorylation of DNA topoisomerase II in etoposide-resistant mutants of human cancer KB cells. Cancer Res 2001, 51:3951-3957.
16. Lage H., Helmbach H., Dietel M., Schadendorf D. Modulation of DNA topoisomerase II activity and expression in melanoma cells with acquired drug resistance. Br J Cancer 2000, 82(2):488-491.
17. Fink D., Aebi S., Howell S.B. The role of DNA mismatch repair in drug resistance. Clin Cancer Res 1998, 4(1):1-6.
18. Tamaichi H., Sato M., Porter A.C.G., Shimizu T., Mizutani S., Takagi M. Ataxia telangiectasia mutated-dependent regulation of topoisomerase II alpha expression and sensitivity to topoisomerase II inhibitor. Cancer Sci 2013, 104(2):178-184. doi:10.1111/cas.12067.
19. Vávrová A., Šimůnek T. DNA topoisomerase IIβ: a player in regulation of gene expression and cell differentiation. Int J Biochem Cell Biol 2012, 44(6):834-837. doi:10.1016/j.biocel.2012.03.005.
20. DeVore R.F., Corbett A.H., Osheroff N. Phosphorylation of topoisomerase II by casein kinase II and protein kinase C: effects on enzyme-mediated DNA cleavage/religation and sensitivity to the antineoplastic drugs etoposide and 4'-(9-acridinyl-amino)methane-sulfon-m-anisidide. Cancer Res 1992, 52:2156-2161.
21. Taki T., Ohnishi T., Arita N., Hiraga S., Hayakawa T. In vivo etoposide-resistant C6 glioma cell line: Significance of altered DNA topoisomerase II activity in multi drug resistance. J Neurooncol 1998, 36(1):41-53.
22. Tomaic V., Pim D., Thomas M., Massimi P., Myers M.P., Banks L. Regulation of the human papillomavirus type 18 E6/E6AP ubiquitin ligase complex by the HECT domain-containing protein EDD. J Virol 2011, 85(7):3120-3127.
23. Clancy J. Characterisation of the gene EDD and its role in cancer, Unpublished doctoral dissertation 2005, Faculty of Medicine, University of New South Wales, Australia.